Successful VivaGel Phase 3 results and NDA planned for rBV
Filed with ASX · · 16 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- VivaGel BV phase 3 results timing and commercialisation
- Starpharma sells Agrochemicals business to Agrium for $35M
- DEP irinotecan outperforms irinotecan in cancer models
- AstraZeneca DEP candidate advance triggers milestone to SPL
- Ansell launches VivaGel condom in Canada
Later from Starpharma
- Starpharma and Monash awarded STEM Business Fellowships
- DEP docetaxel positive phase 1 results, phase 2 commences
- AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
- Starpharma and Peter Mac Cancer Centre awarded DEP Grant
- VivaGel BV granted marketing approval in Australia
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma